Summit Therapeutics PLC (NASDAQ:SMMT) — Market Cap & Net Worth
Market Cap & Net Worth: Summit Therapeutics PLC (SMMT)
Summit Therapeutics PLC (NASDAQ:SMMT) has a market capitalization of $10.92 Billion ($10.92 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2131 globally and #784 in its home market, demonstrating a -1.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Summit Therapeutics PLC's stock price $14.07 by its total outstanding shares 776162645 (776.16 Million). Review Summit Therapeutics PLC debt and liabilities to assess the company's total debt and financial obligations.
Summit Therapeutics PLC Market Cap History: 2015 to 2026
Summit Therapeutics PLC's market capitalization history from 2015 to 2026. Data shows growth from $8.93 Billion to $10.92 Billion (3.13% CAGR).
Index Memberships
Summit Therapeutics PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.45% | #39 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.03% | #240 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.64% | #29 of 263 |
Weight: Summit Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Summit Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Summit Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5656.29x
Summit Therapeutics PLC's market cap is 5656.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.64 Billion | $2.38 Million | -$21.37 Million | 2796.28x | N/A |
| 2017 | $8.60 Billion | $14.17 Million | -$20.16 Million | 606.99x | N/A |
| 2018 | $892.59 Million | $57.09 Million | $10.87 Million | 15.64x | 82.12x |
| 2019 | $1.24 Billion | $43.01 Million | $4.99 Million | 28.87x | 248.67x |
| 2020 | $3.65 Billion | $628.88K | -$38.53 Million | 5800.78x | N/A |
| 2021 | $2.09 Billion | $1.81 Million | -$86.15 Million | 1154.16x | N/A |
| 2022 | $3.30 Billion | $583.19K | -$65.17 Million | 5656.29x | N/A |
Competitor Companies of SMMT by Market Capitalization
Companies near Summit Therapeutics PLC in the global market cap rankings as of June 18, 2026.
Key companies related to Summit Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Summit Therapeutics PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Summit Therapeutics PLC's market cap moved from $8.93 Billion to $ 10.92 Billion, with a yearly change of 3.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.92 Billion | -19.55% |
| 2025 | $13.58 Billion | -1.99% |
| 2024 | $13.85 Billion | +583.72% |
| 2023 | $2.03 Billion | -38.59% |
| 2022 | $3.30 Billion | +57.99% |
| 2021 | $2.09 Billion | -42.77% |
| 2020 | $3.65 Billion | +193.75% |
| 2019 | $1.24 Billion | +39.13% |
| 2018 | $892.59 Million | -89.62% |
| 2017 | $8.60 Billion | +29.44% |
| 2016 | $6.64 Billion | -25.57% |
| 2015 | $8.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Summit Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.92 Billion USD |
| MoneyControl | $10.92 Billion USD |
| MarketWatch | $10.92 Billion USD |
| marketcap.company | $10.92 Billion USD |
| Reuters | $10.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more